Advancing Immunotherapy in Head and Neck Cancer: The IT-MATTERS Study

Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma

Ergomed is proud to have contributed to a significant breakthrough in oncology through the successful delivery of the IT-MATTERS study, one of the largest clinical trials ever conducted globally in Head and Neck Squamous Cell Carcinoma (SCCHN). The study evaluated the use of neoadjuvant Leukocyte Interleukin Injection (LI) immunotherapy in low-risk, locally advanced SCCHN and demonstrated a meaningful improvement in overall survival.

Co-authored by Dr. Dusan Markovic, Ergomed’s Vice President of Global Medical Affairs, this research highlights the potential of immunotherapy to address long-standing gaps in treatment outcomes for this patient population.

Read the full open-access publication in Pathology & Oncology Research and Frontiers to explore the study’s findings and clinical implications.

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.